Constance M. Cultraro, Ph.D.
Affiliations: | 2000 | The George Washington University, Washington, DC, United States |
Area:
Molecular BiologyGoogle:
"Constance Cultraro"Parents
Sign in to add mentor| Shoshana Segal | grad student | 2000 | The George Washington University | |
| (Myc, Max and Mad: Members of a superfamily which interact to regulate cell growth and differentiation.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Roper N, El Meskini R, Maity T, et al. (2024) Functional Heterogeneity in MET Pathway Activation in PDX Models of Osimertinib-resistant EGFR-driven Lung Cancer. Cancer Research Communications. 4: 337-348 |
| Venugopalan A, Lynberg M, Cultraro CM, et al. (2021) SCAMP3 is a mutant EGFR phosphorylation target and a tumor suppressor in lung adenocarcinoma. Oncogene |
| Venugopalan A, Nguyen K, Lynberg M, et al. (2020) Epigenetic Reprogramming Driven By Metabolic Alterations As A Mechanism Of EGFR – Tyrosine Kinase Inhibitor Resistance In Human Lung Adenocarcinoma The Faseb Journal. 34: 1-1 |
| Roper N, Gao S, Maity TK, et al. (2019) APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors. Cell Reports. 26: 2651-2666.e6 |
| Zhang X, Nguyen KD, Rudnick P, et al. (2019) Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V. Molecular & Cellular Proteomics : McP |
| Roper N, Brown A, Sindiri S, et al. (2019) Clonal evolution and osimertinib resistance mechanisms identified by whole exome and transcriptome sequencing in EGFR mutant NSCLC. Journal of Clinical Oncology. 37: 9049-9049 |
| Xhang X, Nguyen KDP, Rudnick P, et al. (2019) Abstract 4528: Quantitative mass spectrometry to interrogate proteomic heterogeneity in metastatic lung adenocarcinoma and validate a novel somatic mutation CDK12-G879V Cancer Research. 79: 4528-4528 |
| Qi Y, Maity TK, Zhang X, et al. (2019) Abstract 1438: Integrated proteogenomics utilizing mass spectrometry to identify MHC-associated neopeptides in EGFR mutant lung adenocarcinoma Cancer Research. 79: 1438-1438 |
| Kim C, Xi L, Cultraro C, et al. (2019) P1.01-27 Serial Circulating Tumor DNA (ctDNA) Analysis of Blood and Saliva Predicts Osimertinib Response and Resistance in EGFR-Mutant NSCLC Journal of Thoracic Oncology. 14: S366 |
| Kim C, Roper N, Hoang C, et al. (2018) Abstract CT106: Local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib Cancer Research. 78 |